NASDAQ
39.29USD
+3.69 (+10.37%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.3B
P/E
—
EPS
—
Beta
0.91
52W range
25.52-40.87
Day range
36.85–39.96
Open
37.60
Prev close
35.60
Volume
929.5K
Avg volume
831.1K
Dividend
0.00
IPO
2020-08-19
https://www.zacks.com/stock/news/2967326/harmony-biosciences-holdings-inc-hrmy-beats-q2-earnings-and-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|yseop_template_4-2967326 · 8/4/2026+0.60
https://www.zacks.com/stock/news/2953957/wall-street-analysts-see-a-27-35-upside-in-harmony-biosciences-hrmy-can-the-stock-really-move-this-high?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2953957 · 7/15/2026+0.60
https://www.zacks.com/stock/news/2953352/hrmy-vs-amgn-which-stock-is-the-better-value-option?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_3-2953352 · 7/14/2026+1.00
https://www.zacks.com/stock/news/2944873/is-hrmy-stock-worth-buying-with-neutral-signals-and-cheap-valuation?cid=CS-STOCKNEWSAPI-FT-analyst_blog_plus|zer_report_insights-2944873 · 6/29/2026+0.20
https://seekingalpha.com/article/4913296-harmony-biosciences-holdings-inc-hrmy-presents-at-goldman-sachs-47th-annual-global-healthcare · 6/9/2026+0.10
https://www.zacks.com/stock/news/2914100/looking-for-a-growth-stock-3-reasons-why-harmony-biosciences-hrmy-is-a-solid-choice?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_11_growth-2914100 · 5/4/2026+1.00
https://www.zacks.com/stock/news/2854049/is-harmony-biosciences-hrmy-stock-undervalued-right-now?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_2-2854049 · 2/11/2026+1.00
https://www.prnewswire.com/news-releases/narcolepsy-market-is-projected-to-grow-at-a-cagr-of-5-6-during-the-forecast-period-20252034-due-to-increasing-disease-awareness-improved-diagnosis-and-expanding-therapeutic-options--delveinsight-302627757.html · 12/2/2025+0.60
https://www.defenseworld.net/2025/11/29/harmony-biosciences-holdings-inc-hrmy-shares-bought-by-american-century-companies-inc.html · 11/29/2025+0.30
https://www.benzinga.com/trading-ideas/long-ideas/25/10/48037150/top-3-health-care-stocks-that-are-preparing-to-pump-in-q4 · 10/6/2025+0.80
https://www.reuters.com/business/healthcare-pharmaceuticals/harmony-biosciences-genetic-disorder-drug-fails-meet-main-goal-late-stage-trial-2025-09-24/ · 9/24/2025-1.00
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
